Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue — Trials · CancerIndex

Clinical trials

Registered studies

169 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 21
Recruiting: 9
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: City of Hope Medical Center
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–13 of 13 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07583810	Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma	recruiting	Phase 2	35	City of Hope Medical CenterOTHER	1	Sep 29, 2026	clinicaltrials
NCT06647732	Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)	active not recruiting	Phase 2	42	Sun Yat-sen UniversityOTHER	1	Sep 15, 2026	clinicaltrials